Clinical trials: MTOR
Colon Cancer
Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients
The goal of this clinical trial is to learn about efficacy of Everolimus in combination with PD-1 in patients with locally advanced and advanced colorectal cancer that cannot be R0 resected.
- Trial name
- NCT06301386
- Testing
- Everolimus, PD-1
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Prostate Cancer Patients With Detectable PSA Following Prostatectomy
Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy
This is a Phase 1 dose escalation study of an investigational agent, everolimus, given in combination with standard radiation therapy, in prostate cancers with a rising PSA following a prostatectomy.
- Trial name
- NCT01548807
- Testing
- Everolimus (RAD001)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Renal Angiomyolipoma
Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
The purpose of this study was to assess the safety and efficacy of everolimus (Afinitor®) in Chinese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC).
- Trial name
- NCT03525834
- Testing
- Everolimus
- Where
- 5 sites in China
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
Topical TOR-582 Treatment of Epistaxis in HHT
People with hereditary hemorrhagic telangiectasia (HHT) often experience frequent and severe nosebleeds that can disrupt daily life and lead to anemia, medical procedures, and reduced quality of life.
- Trial name
- NCT07667413
- Testing
- Topical sirolimus ointment
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Columbia University
Aging
Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly
The ability to mount an effective immune response declines with age, leaving the elderly increasingly susceptible to infectious diseases and cancer.
- Trial name
- NCT02874924
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Blue Rubber Bleb Nevus Syndrome, Venous Malformation
Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation
A prospective, nonrandomized, open-label, single-arm clinical trial to study efficacy of rapamycin (sirolimus) in the treatment of Blue Rubber Bleb Nevus Syndrome, hereditary or sporadic venous malformation
- Trial name
- NCT03767660
- Testing
- Rapamycin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Advanced or Metastatic Solid Tumors, Cancer
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of SF1126 in patients with advanced or metastatic tumors by assessing the dose limiting toxicities (DLTs) and defining the maximum tolerated dose given twice…
- Conditions
- Advanced or Metastatic Solid Tumors, Cancer, Solid Cancers
- Trial name
- SF112600106 (NCT00907205)
- Testing
- SF1126
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Semafore Pharmaceuticals
Prostate Cancer Metastatic
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.
- Trial name
- NCT02407054
- Testing
- LY3023414, Enzalutamide
- Where
- 36 sites in United States
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Peutz-Jeghers Syndrome
Efficacy of Rapamycin (Sirolimus) in the Treatment of Peutz-Jeghers Syndrome
A prospective non-randomized open label single arm clinical trial to examine the efficacy and safety of sirolimus in patients with Peutz-Jeghers Syndrome.
- Trial name
- NCT03781050
- Testing
- Rapamycin
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking Union Medical College Hospital
Dietary Protein
Dietary Protein and Monocyte/Macrophage Mammalian Target of Rapamycin (mTOR) Signaling
High protein low carbohydrate diets have become popular in recent years to help facilitate weight loss. It is controversial if these diets are associated with an increased risk of cardiovascular disease.
- Trial name
- mTOR (NCT03946774)
- Testing
- Dietary protein shake
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
HNSCC
Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations
Preclinical data and limited clinical evidence suggest that Head and Neck Squameous Cell Carcinoma tumors harboring certain mutations may respond well to PI3K/mTOR inhibition (phosphatidylinositol-3-kinase/ mammalian target of…
- Trial name
- HNSCC (NCT03740100)
- Testing
- Bimiralisib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Inflammatory Bowel Diseases
Atorvastatin Efficacy and Safety in Patients With Ulcerative Colitis
Statins exert numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of their basic lipid-lowering properties.
- Trial name
- NCT05567068
- Testing
- Atorvastatin 80mg, Mesalamine
- Where
- Egypt
- Volunteers
- 54 people
- Sponsor
- Tanta University
Renal Transplant
Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction
The purpose of this study is to evaluate whether conversion to everolimus (Zortress®), allowing the elimination or reduction of calcineurin inhibitors, will reduce nephrotoxicity (measured by increased creatinine clearance) and…
- Trial name
- NCT01935128
- Testing
- Arm 1 Everolimus/Reduced dose tacrolimus
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Toledo Health Science Campus
Covid19
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in adults age ≥ 65 years to inform the design of a subsequent pivotal trial.
- Trial name
- NCT04584710
- Testing
- RTB101
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Restorbio Inc.
Estrogen Receptor Positive Breast Cancer
A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer
This is an open-label, multicentre, 4-arm randomised phase II trial of fulvestrant + AZD2014 versus fulvestrant + everolimus versus fulvestrant alone in patients with ER-positive, HER2-negative advanced or metastatic breast…
- Trial name
- MANTA (NCT02216786)
- Testing
- AZD2014, Everolimus, Fulvestrant
- Where
- 79 sites in France, Georgia and 7 more
- Volunteers
- 333 people
- Sponsor
- Queen Mary University of London
Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour
Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors
The purpose of this study is: 1. To determine the optimal recommended phase II dose of two investigational study drugs, LBH589 and RAD001, given in combination in all solid tumors (With enrichment for EBV-Driven tumors). 2.
- Trial name
- NCT01341834
- Testing
- LBH589 and RAD001
- Where
- Singapore
- Volunteers
- 49 people
- Sponsor
- National Cancer Centre, Singapore
Hepatitis C Recurrence After Liver Transplant
The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation
Background: Hepatitis C recurrence, which invariably occurs in viremic liver transplant (LT) recipients, associated with accelerated liver fibrosis leading to established graft cirrhosis in 40-20% of patients in 5 years with…
- Trial name
- NCT01707849
- Testing
- EVL arm, MMF arm
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- Hospital Vall d'Hebron
1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer
A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )
1. This is a multi-center clinical study to evaluate dual mTORC1/2 inhibitor (ATG 008) or selective inhibitor of nuclear export compound (ATG-010) in combination with chemotherapy in patients with relapsed or metastatic ovarian…
- Trial name
- PORCH (NCT04998760)
- Testing
- ATG-008, ATG-010
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Qi Zhou
Mild Cognitive Impairment, Metabolic Syndrome
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation
The study explores whether selective memory complaints (SMC), mild cognitive impairment (MCI) and the comorbidity of Metabolic Syndrome symptomatic of peripheral and cerebral hypo-metabolism with corresponding epigenetic shifts…
- Trial name
- NCT03319173
- Testing
- Dietary intervention
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Bristlecone Health, Inc.
Cancer, Advanced Hepatocellular Carcinoma
Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients
The main purpose of the study is to establish a safe dose of AZD8055 in patients with mild or moderate liver disease by providing information on any potential side effects this drug may cause and collecting data about how…
- Trial name
- NCT00999882
- Testing
- AZD8055
- Where
- 3 sites in Hong Kong, South Korea
- Volunteers
- 26 people
- Sponsor
- AstraZeneca